Omexa Formulary plans to set up a new manufacturing unit for monoclonal antibodies and formulation products with an investment of ?95 crore near Tindivanam, about 130 km south of Chennai, Tamil Nadu. The proposed unit will be developed on a four-acre site within TANSIDCO Industrial Park in Pellakuppam Village, Tindivanam Taluk, Villupuram district.

As per document filed for environmental clearance (EC), the facility will have an annual production capacity of 520 kg of monoclonal antibodies and 1,64,000 units per month of formulation products. Omexa plans to produce 30 monoclonal antibody products, along with two formulation products - prefilled syringes and vials, as well as lyophilised vials, and will meet the growing demand for monoclonal antibodies in both domestic and international regions.

The project is expected to generate employment for about 120 individuals. This project supports India’s goal to become a global supplier of biological products, wherein the company will use its expertise in fermentation technology to develop a wide range of generic biologics, monoclonal antibodies, and therapeutic proteins.